Home › Conditions › Brain Metastases
Oncology
Brain Metastases
Brain metastases occur in 20–40% of patients with systemic cancer — commonest primaries are lung, breast, melanoma, renal, and colorectal. Presentation includes morning headache (worse lying flat), focal neurology, and seizures. Dexamethasone 8mg BD reduces cerebral oedema. Raised ICP is an emergency: dexamethasone 16mg IV stat + mannitol + urgent neurosurgical review.
NICE NG99 / ESMO Brain Metastases Guideline
The pathway
Assess and stabilise
Emergency management of raised ICP
- Dexamethasone 16mg IV stat (emergency dose for herniation)
- Mannitol 20%: 1g/kg IV over 20 minutes for acute herniation
- Head of bed at 30°
- Hyperventilate if intubated: target PaCO₂ 4.0–4.5 kPa
- Contact neurosurgery immediately
Imaging
- CT head with contrast acutely if raised ICP suspected (before MRI if unstable)
- MRI brain with gadolinium: gold standard for number, size, location, leptomeningeal disease
- CT chest/abdomen/pelvis if primary unknown
- PET-CT if oligometastatic disease and curative intent being considered
Seizure prophylaxis and management
- Do NOT give prophylactic anticonvulsants in seizure-naive patients (NICE NG99)
- First seizure with brain metastasis: levetiracetam 500mg BD PO or IV (preferred over phenytoin — fewer drug interactions)
- Titrate levetiracetam to 1000–3000mg/day based on response
- DVLA notification: patient must not drive — document advice
Dexamethasone for symptomatic oedema
- Dexamethasone 8mg BD for symptomatic peritumoral oedema (headache, focal deficit)
- Do NOT treat asymptomatic patients — no survival benefit, significant side effects (Cushingoid, myopathy, glucose dysregulation)
- Taper over weeks once definitive treatment started
- Add omeprazole 20mg OD and monitor blood glucose
Prognosis: GPA score
- Graded Prognostic Assessment (GPA): based on age, KPS, number of metastases, extracranial metastases, histology-specific factors
- Guides treatment intensity — discuss at neuro-oncology MDT
- Median survival: 3 months (poor GPA) to >20 months (good GPA, favourable histology e.g. HER2+ breast)
Definitive treatment options
- Single/oligometastatic (1–3): stereotactic radiosurgery (SRS) preferred — local control without neurocognitive side effects
- Single accessible lesion with mass effect or diagnostic uncertainty: surgical resection + post-op SRS
- Multiple metastases (>3): whole brain radiotherapy (WBRT) or best supportive care based on performance status
- Leptomeningeal disease: intrathecal chemotherapy (methotrexate) ± craniospinal radiation — very poor prognosis
- Chemo-sensitive histology (SCLC, germ cell, lymphoma): systemic chemotherapy may control CNS disease
Drugs
| Drug | Dose | Route | Notes |
|---|---|---|---|
| Dexamethasone | 8mg BD (16mg IV stat in emergency) | PO or IV | 8mg BD for symptomatic oedema. 16mg IV stat for acute raised ICP or herniation. Taper over weeks. Monitor blood glucose. |
| Mannitol 20% | 1g/kg IV over 20 minutes | IV | Acute cerebral herniation. Ensure Foley catheter in situ. Monitor serum osmolarity (target <320 mOsm/kg). |
| Levetiracetam | 500mg BD | PO or IV | Preferred anticonvulsant for brain metastasis-associated seizures. Titrate to 1000–3000mg/day. Fewer drug interactions than phenytoin. |
| Omeprazole | 20mg OD | PO | Gastric protection with dexamethasone. Check for interactions with systemic anticancer therapy. |
| Lorazepam | 4mg IV | IV | Acute seizure management. See status epilepticus pathway for full protocol. |
When to escalate
- Falling GCS or papilloedema — raised ICP: dexamethasone 16mg IV stat + mannitol 1g/kg, neurosurgery emergency
- Cushing's triad (hypertension, bradycardia, irregular respiration) — impending tonsillar herniation, emergency neurosurgery
- Status epilepticus — full lorazepam protocol, ITU, neurology input
- Leptomeningeal disease suspected (cranial nerve palsies, cauda equina, multilevel spinal cord signs) — MRI spine, neuro-oncology MDT
- Single large accessible metastasis with significant mass effect — emergency neurosurgical resection discussion
- New neurological presentation in patient on immune checkpoint inhibitor — consider immune-mediated encephalitis; neurology and oncology review
Reference: NICE NG99 Brain Tumours (Primary and Metastatic) 2018 / ESMO Brain Metastases Clinical Practice Guidelines 2021
Practise and explore
Practise a case or explore differentials here on the website. The optional browser app adds personal learning tools and saved progress.